Celldex shares fall after it drops skin disease drug study
21/07/2026 21:53
BUZZ-Celldex shares fall after it drops skin disease drug study ** Drug developer Celldex's shares CLDX.O fall 6.3% to $33.42 in extended trading
** Co says it will discontinue development of experimental drug barzolvolimab for prurigo nodularis, a chronic skin disease
** Barzolvolimab failed to meet the main goal and key secondary goals in a mid-stage study
** As of Tuesday's close, stock has risen ~31% YTD
(Reporting by Anhata Rooprai in Bengaluru)
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials